2009
DOI: 10.1097/mcg.0b013e3181775e6a
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: RVR and absence of cirrhosis are the strongest predictive factors of SVR in HCV genotype 1 patients. Assessment of RVR is very useful in all pretreatment status patients in predicting SVR and provides information for individualizing therapy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
23
0

Year Published

2010
2010
2017
2017

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 19 publications
(23 citation statements)
references
References 21 publications
0
23
0
Order By: Relevance
“…Several previous studies reported that patients who achieved a rapid virologic response, in which serum HCV RNA become undetectable at 4 weeks after starting therapy, had a high likelihood of achieving a sustained virologic response [Martinez-Bauer et al, 2006;Poordad et al, 2008;de Segadas-Soares et al, 2009;Martinot-Peignoux et al, 2009]. In addition, several recent studies reported the predictive value of the degree of reduction in serum HCV RNA levels at 4 weeks after starting therapy [Yu et al, 2007;Huang et al, 2010;Toyoda et al, 2011].…”
Section: Discussionmentioning
confidence: 94%
See 1 more Smart Citation
“…Several previous studies reported that patients who achieved a rapid virologic response, in which serum HCV RNA become undetectable at 4 weeks after starting therapy, had a high likelihood of achieving a sustained virologic response [Martinez-Bauer et al, 2006;Poordad et al, 2008;de Segadas-Soares et al, 2009;Martinot-Peignoux et al, 2009]. In addition, several recent studies reported the predictive value of the degree of reduction in serum HCV RNA levels at 4 weeks after starting therapy [Yu et al, 2007;Huang et al, 2010;Toyoda et al, 2011].…”
Section: Discussionmentioning
confidence: 94%
“…Recent reports have emphasized the importance of evaluating the viral dynamics at 4 weeks after starting therapy to predict a sustained virologic response. A rapid virologic response, in which serum HCV RNA is undetectable at 4 weeks after starting therapy, has been the strongest predictive factor of a sustained virologic response reportedly [Martinez-Bauer et al, 2006;Poordad et al, 2008;de Segadas-Soares et al, 2009;Martinot-Peignoux et al, 2009]. In addition, the predictive value of reduced serum HCV RNA levels at 4 weeks after starting therapy has been clarified further, and a !3 log 10 reduction in HCV RNA levels at 4 weeks after starting therapy has high predictive value that a patient will achieve a sustained virologic response as a final outcome, even in the absence of a rapid virologic response [Toyoda et al, 2011].…”
Section: Introductionmentioning
confidence: 95%
“…In a retrospective study on Southern Brazilian patients with chronic hepatitis and HCV genotype 1 infection, SVR was achieved in only 35.3% of patients (114/323), although this may have occurred because a large proportion of the patients presented advanced fibrosis (F3/F4 = 74%) 24 . However, previous Brazilian studies have demonstrated SVR rates of 44-52% in genotype 1 HCV infection among patients who were not enrolled in medical trials [25][26][27] . Improvements in the management of patients with chronic HCV genotype 1 infection are essential.…”
Section: Discussionmentioning
confidence: 99%
“…For these reasons, it is important to predict, with high reliability, the likelihood that a patient will achieve an SVR to PEG-IFN and ribavirin combination therapy as early as possible in order to prevent unnecessary treatment. More recent reports have emphasized the importance of a rapid virologic response (RVR), in which serum HCV RNA levels are undetectable at 4 weeks after starting therapy, for predicting an SVR [20][21][22][23]. In the present study, we determined the predictive value of decreased serum HCV RNA levels at 4 weeks after starting therapy compared to that of an EVR at 12 weeks.…”
Section: Introductionmentioning
confidence: 96%